Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.00    2.50 (5.88%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £86.34m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Placing

12 Feb 2009 16:44

RNS Number : 2541N
Iofina PLC
12 February 2009
 



Iofina plc

Placing of £5 million

12 February 2009

The Directors of Iofina plc ("Iofina" or the "Company"), the gas and iodine production and development company, are pleased to announce that the Company has conditionally raised £5 million (before expenses) through a placing of 9,090,000 new ordinary shares of 1p each in the Company (the "Placing Shares"), at a price of 55p per share (the "Placing"). 

The net proceeds of the Placing will be primarily applied to pursue several new opportunities in the iodine derivatives market that have recently emerged. If entered into, the Directors believe the ensuing vertical integration through both production and derivatives should result in significantly better margins.

The Placing Shares will be subscribed for by certain new and existing institutional shareholders of the Company. The Placing is conditional, inter alia, on admission of the Placing Shares to trading on AIM ("Admission").

The Placing Shares will represent 8.83 per cent. of the then enlarged issued share capital of the Company immediately following Admission.  The number of ordinary shares of 1p each ("Ordinary Shares") in issue following the Placing, and the total number of voting rights, will be 102,906,114. The Placing Shares will rank pari passu with existing Ordinary Shares. Application will be made for Admission which is expected to take place on 18 February 2009.

David Schneider, Chief Executive, commented: "Despite extremely difficult capital market conditions, we have been delighted by the response of both new and existing institutional investors who share our excitement and vision with respect to vertically integrating Iofina into the iodine derivatives market The Placing was done at a 12% premium to the previous day's closing price.

With approximately £17m of net cash on the balance sheet on completion of the Placing, Iofina will be fully funded both to progress the Altantis prospect through to full development and positive cash flow generation, while at the same time move Iofina Chemical into the iodine derivatives market. This move will enhance Iofina's strategic position in the US where the large domestic blue chip end users of iodine derivatives currently rely heavily on imports from Chile and Japan. We continue to remain excited about Iofina's prospects and our ability to create value for our shareholders.

For further information, please contact: 

Lance Baller

Iofina plc

Tel: +44(0)20 3006 3135 x301

 

Nominated Adviser:

James Harris/Angela Peace

Strand Partners Limited

Tel: +44(0)20 7409 3494

 

Broker:

Rory Scott

Mirabaud Securities Limited

Tel: +44(0)20 7878 3360

 

Media Contact:

Chelsea Hayes

Pelham Public Relations

Tel: +44 (0)20 7743 6675

 

About Iofina

Iofina is involved in the exploration and production of both iodine and natural gas which have been discovered on acreages which the Company holds. The presence of both iodine and natural gas allows the Iofina group of companies (the "Group") to generate dual revenue streams over a single cost structure. The dual revenue approach has worked successfully in the Mobara field in Japan which has been producing iodine and natural gas for over the past 50 years. Iodine is a rare element that is only produced in a few countries in the world with over 79 per cent. coming from Chile (58 per cent.) and Japan (21 per cent.). This has resulted in the US and Western Europe becoming major net importers to meet growing demands from pharmaceutical and industrial manufacturers. Iodine demand is growing at 6.6 per cent. per annum driven by a combination of increased usage in a wide variety of sectors from pharmaceutical manufacturing, LCD screen manufacturing, medical imaging, cosmetics, biocides in paints and pesticides, as well as the emergence of new uses for iodine and greater consumption from developing countries such as India and China. The Group's proprietary Wellhead Extraction Technology® method will allow low cost production metrics and high operational efficiencies compared to other large iodine/gas fields in MobaraJapan and OklahomaUSA. Iofina owns a thirteen mile pipeline that ultimately links to the TransCanada pipeline. Iofina currently has leased over 60,000 net acres in the Atlantis Prospect and approximately 30,000 net acres in its Triton Prospect. MHA Petroleum Consultants, Inc., the Competent Person, estimates that as of 1 February 2008 and, based on Iofina's core c.28,000 acres at that time in the Atlantis Prospect, Iofina has 100.6 million kg of iodine in place and has 155.6Bcf of natural gas in place, making the Atlantis Prospect the largest known iodine resource in North America. The directors of the Company believe that Iofina's low cost development strategy and its dual revenue streams are expected to provide both excellent margins and reduced revenue volatility since the two product streams are unrelated relative to their respective markets.

Iofina is traded on the London Stock Exchange's AIM Market under the ticker: IOF. 

www.iofina.com 

Wellhead Extraction Technology® and WET® are registered trademarks of Iofina Natural Gas, Inc.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROIDGGMZVZZGLZM
Date   Source Headline
5th Apr 20128:05 amRNSPurchase of Production Site & Recycling Initiative
2nd Apr 20125:01 pmRNSHolding(s) in Company
29th Mar 201212:11 pmRNSHolding(s) in Company
19th Mar 20127:00 amRNSCorporate Update
25th Nov 20117:00 amRNSDirector/PDMR Shareholding
24th Nov 20117:00 amRNSDirector/PDMR Shareholding
17th Oct 20117:00 amRNSHolding(s) in Company
27th Sep 20117:00 amRNSHalf Yearly Report
9th Aug 20117:00 amRNSTrading Update
30th Jun 20114:42 pmRNSResult of AGM
24th Jun 201111:42 amRNSHolding(s) in Company
8th Jun 20117:00 amRNSAmbrian Partners Appointed Joint Broker to Iofina
7th Jun 20117:00 amRNSIofina Reports Audited Full Year Financials
31st May 20116:03 pmRNSHolding(s) in Company
4th May 20114:32 pmRNSHolding(s) in Company
4th May 20114:29 pmRNSHolding(s) in Company
28th Apr 201112:58 pmRNSHolding(s) in Company
20th Apr 20117:00 amRNSPlacing
13th Apr 20116:28 pmRNSHolding(s) in Company
25th Mar 20117:00 amRNSContract Win
18th Mar 20117:00 amRNSHolding(s) in Company
1st Mar 20113:35 pmRNSHolding(s) in Company
27th Jan 20115:27 pmRNSHolding(s) in Company
12th Jan 20114:40 pmRNSSecond Price Monitoring Extn
12th Jan 20114:35 pmRNSPrice Monitoring Extension
3rd Dec 201012:46 pmRNSOperations Update
19th Oct 20105:30 pmRNSHolding(s) in Company
29th Sep 20109:26 amRNSHolding(s) in Company
28th Sep 20107:01 amRNSInterim Results
28th Sep 20107:00 amRNSAppointment of Finance Director
31st Aug 20107:00 amRNSFourth Extraction and Collection Agreement Signed
16th Jul 20105:57 pmRNSHolding in Company - Replacement
16th Jul 20105:02 pmRNSHoldings in Company
7th Jul 201010:00 amRNSResult of AGM
4th Jun 20107:00 amRNSFinal Results
20th May 20107:00 amRNSNew Agreement Signed and Operations Update
4th May 20107:00 amRNSIssuance of Permit
14th Apr 20107:00 amRNSThird Party Iodine Agreement Signed
22nd Mar 20108:36 amRNSFirst Third Party Iodine Extraction and Collection
22nd Mar 20107:00 amRNSRe Iodine Extraction and Collection Agreement
8th Mar 20107:02 amRNSOperations Update
8th Mar 20107:00 amRNSManagement changes
12th Jan 20103:09 pmRNSDirectorate Change
8th Jan 20107:00 amRNSDirector's Dealings
11th Dec 20096:00 pmRNSHolding in Company
22nd Oct 20095:14 pmRNSChange of Name of Nominated Adviser
19th Oct 20094:07 pmRNSExercise of Options
30th Sep 20097:00 amRNSHalf Yearly Report
10th Aug 200911:13 amRNSManagement Appointments
27th Jul 20097:00 amRNSAcquisition and Operations Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.